Araki, T., Sangtian, J., Ruanpeng, D., Tummala, R., Clark, B., Burmeister, L., Peterson, D., Venteicher, A. S., Kawakami, Y., 2021. Acute elevation of interleukin 6 and matrix metalloproteinase 9 during the onset of pituitary apoplexy in Cushing's disease.. Pituitary, 24 (6): 859-866.
doi: https://doi.org/10.1007/s11102-021-01157-0
PubMed ID: 34041660
Araki, T., Tone, Y., Yamamoto, M., Kameda, H., Ben-Shlomo, A., Yamada, S., Takeshita, A., Yamamoto, M., Kawakami, Y., Tone, M., Melmed, S., 2021. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.. The Journal of clinical endocrinology and metabolism, 106 (9): e3346-e3363.
doi: https://doi.org/10.1210/clinem/dgab387
PubMed ID: 34061962
Araki, T., Liu, X., Kameda, H., Tone, Y., Fukuoka, H., Tone, M., Melmed, S., 2017. EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis.. J. Endocr. Soc., 1 (2): 127-143.
Araki, T., Liu, N., Tone, Y., Cuevas-Ramos, D., Heltsey, R., Tone, M., Melmed, S., 2016. E2F1-mediated human POMC expression in ectopic Cushing’s syndrome. . Endocr Relat Cancer., 23 (11): 857-870.
Cuevas-Ramos, D., Hong, J., Ben-Shlomo, A., Tone, Y., Tone, M., Melmed, S., 2015. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease.. Journal of Clinical Endocrinology and Metabolism, 100 (7): 2557-64.
